Home > Healthcare > Medical Devices > Diagnostic Devices > Cervical Cancer Diagnostics Market

Cervical Cancer Diagnostics Market Share

Report ID: GMI3774
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Cervical Cancer Diagnostics Market Share

The cervical cancer diagnostics industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Becton, Dickinson and Company (BD), Hologic, Inc., QIAGEN, among others have a notable presence in the market.

Cervical Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the cervical cancer diagnostics industry include:

Abbott Laboratories
Arbor Vita Corporation
Becton, Dickinson and Company (BD)
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fujirebio Diagnostics, Inc.
Hologic, Inc.
QIAGEN
Seegene Inc
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of cervical cancer diagnostics reached USD 7.2 billion in 2023 and is set to cross USD 11.5 billion by 2032, propelled by the increasing prevalence of cervical cancer, particularly in low and middle-income countries.

The pap smear tests segment held over USD 2.9 billion in 2023, owing to its inclusion in routine screening programs, accessibility, and affordability.

North America market accounted for USD 2.9 billion in 2023, due to the region's relatively high prevalence of cervical cancer.

Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company (BD), Danaher Corporation, F. Hoffmann-La Roche Ltd, Fujirebio Diagnostics, Inc., Hologic, Inc., QIAGEN, Seegene Inc, Thermo Fisher Scientific Inc.are some of the major industry contenders.